| Date Filed | Type | Description |
| 10/06/2023 |
SC 13D/A
| HighCape Capital, L.P. reports a 68% stake in Elutia Inc. |
| 10/03/2023 |
D
| Form D - Notice of Exempt Offering of Securities: |
| 08/14/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/14/2023 |
8-K
| Quarterly results |
| 07/13/2023 |
8-K
| Regulation FD Disclosure, Other Events, Financial Statements and Exhibits Interactive Data |
| 06/09/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 05/12/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/10/2023 |
8-K
| Quarterly results |
| 04/27/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/27/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/21/2023 |
8-K
| Quarterly results |
| 03/23/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/22/2023 |
8-K
| Quarterly results |
| 03/21/2023 |
SC 13G/A
| Endurant Capital Management LP reports a 4.9% stake in Aziyo Biologics, Inc. |
| 03/20/2023 |
8-K
| Quarterly results |
| 02/14/2023 |
SC 13G/A
| Endurant Capital Management LP reports a 10.7% stake in Aziyo Biologics, Inc. |
| 02/14/2023 |
SC 13G/A
| Endurant Capital Management LP reports a 10.7% stake in Aziyo Biologics, Inc. |
| 02/13/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 01/09/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data|
Docs:
|
"Aziyo Biologics Announces Record Annual Net Sales in Preliminary Fourth Quarter and Full Year 2022 Topline Results SILVER SPRING, Md., January 9, 2023 — Aziyo Biologics, Inc. , a biologics company with a portfolio of regenerative products aimed at improving compatibility between medical devices and the patients they treat, today announced preliminary net sales results for its fourth quarter and full year ended December 31, 2022. Preliminary Fourth Quarter and Full Year 2022 Net Sales Results · Anticipate fourth quarter 2022 net sales of approximately $12.5-$12.7 million, an increase of 15%-17% compared to the same prior year period · Anticipate full year 2022 record net sales of approximately $49.0-$49.2 million, an increase of 3%-4% compared to the prior year and, after excl..." |
|
| 12/30/2022 |
8-K
| Quarterly results |
| 12/15/2022 |
8-K
| Quarterly results |
| 12/14/2022 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 12/07/2022 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 12/05/2022 |
8-K
| Quarterly results |
| 12/01/2022 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 11/30/2022 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 11/28/2022 |
8-K
| Quarterly results |
| 11/17/2022 |
8-K
| Quarterly results |
| 11/14/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 10/24/2022 |
8-K
| Quarterly results |
| 10/13/2022 |
8-K
| Entry into a Material Definitive Agreement Interactive Data |
| 09/09/2022 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 08/31/2022 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 08/31/2022 |
8-K
| Asset disposition |
|